Background: Everolimus (E) plus exemestane are approved for advanced hormone receptor (þ) breast cancer (BC) after progression on non-steroidal aromatase inhibitors. The role of E is less well defined in other BC phenotypes and with other drugs. We conducted a systematic review and meta-analysis to assess the efficacy and safety of adding E to standard of care (SoC) in advanced BC regardless of tumor phenotype and treatment type.
Background: Real-world data on health-related quality of life (HRQoL) in women with HRþ/HER2-advanced/metastatic breast cancer (ABC/mBC) are limited. This study aims to address this gap. Methods: MARIA is a non-interventional, prospective, multi-center study that includes women in Italy and Germany initiating their first or second therapy in the HRþ/ HER2-ABC/mBC setting. Breast cancer specific HRQoL was assessed using the Functional Assessment of Cancer Therapy-Breast (FACT-B). We report baseline clinical characteristics and HRQoL assessments at enrollment (baseline) and at 3 and 6 months for the first 262 patients enrolled. Change from baseline was calculated for patients with both baseline and follow-up measurement and tested for statistical significance using t-tests for the overall cohort and within subgroups stratified by visceral and bone metastases status. Results: Median age was 61 years and 46% had visceral disease. At enrollment, 32% were receiving endocrine monotherapy, 34% chemotherapy alone, 28% endocrine/ targeted therapy combinations, and 7% other regimens. A statistically significant (p < 0.05) deterioration was observed in the overall cohort at Month 3 for both ) and FACT-G (-4.1 [13.2] ) and at Month 6 for the total FACT-G score (-2.1 [12.7] ). In the subgroup with visceral and bone metastases, a statistically significant (p < 0.05) deterioration was observed in FACT-G scores at 3 months: (-6.6 [16.1] ) and at 6 months (-3.6 [12.3] ) while no significant change was observed in FACT-B scores. A statistically significant (p < 0.05) deterioration from baseline was observed in the subgroup with visceral disease and without bone metastases in FACT-B score at 3 months (mean [SD]: -6.7 [13.9] and at 6 months (-3.9 [16.6] ), respectively while no significant change was observed in FACT-G scores. Conclusions: A statistically significant deterioration was observed in HRQOL scores at some time points after initiating a new line of therapy in the overall cohort and some subgroups of HRþ HER2-MBC patients in a prospective study In Italy and Germany. Further follow-up is ongoing to examine the longer-term impact of therapy on HRQoL.
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336P Everolimus in advanced breast cancer: A systematic review and metaanalysis
Methods: The electronic databases PubMed and EMBASE, were searched for eligible randomized trials. Pooled hazard ratios (HR) for progression free survival (PFS) and overall survival (OS) and pooled risk ratios (RR) and odds ratios (OR) for objective response rates (ORR), clinical benefit rates (CBR) and grade 3 or higher toxicity were meta-analyzed using the generic inverse variance, the Mantel-Henszel and Peto method. To account for between-studies heterogeneity, random-effect models were used. Subgroup analyses compared survival outcomes by tumor phenotype. Results: Data of 2,693 patients from 7 trials were analyzed. The addition of E to the SoC reduced the risk of disease progression by 33% (7 trials, HR 0.67, 95%CI 0.52-0.86). This did not translate into an OS benefit (4 trials, HR 0.91, 95%CI 0.62-1.33). In addition, E improved the ORR (6 trials, RR 0.91, 95%CI 0.85-0.97) and CBR (7 trials, RR 0.79 95%CI 0.65-0.97) while it increased the risk of developing ! grade 3 toxicity including stomatitis (OR 5.00, 95%CI 3.63-6.89) and pneumonitis (OR 3.13, 95%CI 1.83-5.36). The PFS benefit was more prominent for patients with hormone receptor (þ) / HER2 (-) (HR 0.51, 95%CI 0.43-0.59) than HER2 (þ) disease (HR 0.83, 95%CI 0.73-0.96; p for subgroup differences<0.001). For the HER2 (þ) subgroup, the PFS benefit was restricted to hormone receptor (-) patients (HR 0.65, 95%CI 0.53-0.81 and HR 0.99, 95%CI 0.83-1.19 for hormone receptor (þ) patients; p for subgroup differences 0.004).
Conclusions: E reduces the risk of disease progression in hormone receptor (þ) advanced BC independent of endocrine therapy type. In HER2 (þ) patients, the benefit is limited for hormone receptor (-) patients. Given the use of newer drugs in the first line, real-world data are needed to confirm whether the benefit persists for patients who develop resistance to CDK4/6 inhibitors.
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337P First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? and Paloma2 trials showed that the addition of a CDK4/6 inhibitor to an aromatase inhibitor (AI) increases the PFS. The use of the combination for the first-line treatment of bone-only disease (BoD) is widely discussed. Our meta-analysis aims to explore the role of the new endocrine strategies in BoD. Methods: The Prisma statement was used. A systematic review of electronic databases identified the phase III clinical trials comparing the standard AI to a novel experimental strategy. The hazard ratios (HR) for PFS for the subgroup of BoD were pooled in a meta-analysis. The heterogeneity of the data was evaluated by Chi-square Q test and I 2 statistic. Results: 7 studies were included in the analyses. 4 trials explored the role of CDK4/6 inhibitors (Monaleesa2 and 7, Monarch3 and Paloma2), 2 trials analyzed Fv þ AI (SWOG and FACT), while one trial studied Fv monotherapy (FALCON). 5 trials reported data regarding the BoD, while 2 trials included the BoD in the non-visceral disease. Overall, the meta-analyses showed a PFS advantage for the experimental arms [HR 0.67 p 0.01], with a significant moderate/high heterogeneity [I 2 69.88% p 0.003].
Only the FALCON and Paloma2 showed a significant improvement in PFS, respectively for Fv and Palbociclib þ Letrozole. Considering only trials reporting data for BoD, the experimental arms significantly improved the PFS [HR 0.60 p 0.001], with a low/moderate non-significant heterogeneity [I 2 37.73% p 0.17].
Conclusions:
The meta-analyses of trials reporting data for BoD, showed that the novel strategies are able to improve the PFS. Nonetheless, only Palbociclib þ Letrozole provided statistically significant data of advantage in this setting. In clinical trials, BoD is often included in the non-visceral disease subgroup. Future clinical trials should take into account the differences in natural history and better prognosis of BoD, in order to define the best approach to these patients.
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338P Real world treatment patterns associated with palbociclib combination therapy in Germany: Results from the IRIS study 76% of palbociclib þ AI patients started on 125 mg compared to 65% of palbociclib þ fulvestrant patients. Dose reductions occurred in only 28 (10.9%) patients (7.4% of those who started at 125 mg/day) and a cycle delay occurred in 1 (3.4%) patient. Dose reduction rates were 10.8% in palbociclib þ AI and 11.1% in palbociclib þ fulvestrant.
Conclusions: In the real world setting, rates of dose reduction were low, and were similar between palbociclib þ AI and palbociclib þ fulvestrant in HRþ/HER2-ABC/ MBC patients in Germany.
